Skip to main content
OpenTrials
Completed

NCT Number: NCT00325806

Ramipril - Hypertension

Primary objective:

Mean values of systolic and diastolic office blood pressure

Secondary objectives:

Total mortality, occurrence of cardio- and cerebrovascular events, change of mean blood pressure (ABPM : Ambulatory Blood Pressure Monitoring) during the observation

Completed

Looking for future studies?

Notify Me

Key information

Age range

50 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • no previous antihypertensive therapy
  • high-normal blood pressure according to the JNC-VI definition (systolic 130 - 139 and/or diastolic 85 - 89 mmHg)

Exclusion criteria

  • antihypertensive therapy
  • blood pressure greater 140/90 mmHg or ABPM greater 135/85 mmHg

Treatment and study plan

Ramipril

Drug

Primary outcomes

  1. Mean systolic and diastolic 24-hour blood pressure in ABPM

Secondary outcomes

  1. Overall mortality and total number of cardiovascular and cerebro-vascular events

  2. Changes in mean blood pressure readings over time

  3. Reasons for admissions to hospital/-stays

  4. Occurrence of pathological fasting glucose levels in serum/pathological HbA1c levels.

Sponsors and collaborators

Lead sponsor

Sanofi

Industry

Registry information

Official study title

Prevention of Hypertension in Patients With High-Normal Blood Pressure With the Angiotensin-Converting-Enzyme-Inhibitor Ramipril - a Randomised Prevention Trial of the German Hypertension League.

Important dates

Study start
2000
Primary completion
2005
Study completion
2005
First posted
May 15, 2006
Registry last updated
Mar 8, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.